TN2013000325A1 - (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases - Google Patents

(1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases

Info

Publication number: TN2013000325A1
Authority: TN; Tunisia
Prior art keywords: triazolo; inhibitors; phosphodiesterases; quinoxaline derivatives; quinoxaline
Prior art date: 2011-01-31

Application number

TNP2013000325A

Other languages

English (en)

Inventor

Hans-Joachim Lankau

Barbara Langen

Christian Grunwald

Norbert Höfgen

Hans Stange

Rita Dost

Ute Egerland

Original Assignee

Boehringer Ingelheim Int

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-01-31

Filing date

2013-07-29

Publication date

2015-01-20

2013-07-29 Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int

2015-01-20 Publication of TN2013000325A1 publication Critical patent/TN2013000325A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Addiction (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Emergency Medicine (AREA)
Gynecology & Obstetrics (AREA)
Psychology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)
Cardiology (AREA)
Child & Adolescent Psychology (AREA)
Pregnancy & Childbirth (AREA)
Anesthesiology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)

TNP2013000325A 2011-01-31 2013-07-29 (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases TN2013000325A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161437848P	2011-01-31	2011-01-31
PCT/EP2012/051546 WO2012104293A1 (fr)	2011-01-31	2012-01-31	Dérivés de (1,2,4)triazolo[4,3-a]quinoxaline utilisés comme inhibiteurs des phosphodiestérases

Publications (1)

Publication Number	Publication Date
TN2013000325A1 true TN2013000325A1 (en)	2015-01-20

Family

ID=45833359

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TNP2013000325A TN2013000325A1 (en)	2011-01-31	2013-07-29	(1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases

Country Status (25)

Country	Link
US (1)	US9540379B2 (fr)
EP (1)	EP2670754B1 (fr)
JP (1)	JP6027547B2 (fr)
KR (1)	KR20140019342A (fr)
CN (1)	CN103459395A (fr)
AR (1)	AR085099A1 (fr)
AU (1)	AU2012213471B2 (fr)
BR (1)	BR112013019354A2 (fr)
CA (1)	CA2824929A1 (fr)
CL (1)	CL2013002003A1 (fr)
CO (1)	CO6811848A2 (fr)
EA (1)	EA023792B1 (fr)
EC (1)	ECSP13012824A (fr)
GE (1)	GEP20156333B (fr)
IL (1)	IL226826A (fr)
MA (1)	MA34844B1 (fr)
MX (1)	MX2013008667A (fr)
PE (1)	PE20141023A1 (fr)
PH (1)	PH12013501355A1 (fr)
SG (1)	SG192210A1 (fr)
TN (1)	TN2013000325A1 (fr)
TW (1)	TWI535718B (fr)
UA (1)	UA111963C2 (fr)
UY (1)	UY33888A (fr)
WO (1)	WO2012104293A1 (fr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2012277912B2 (en) *	2011-06-27	2017-03-23	Janssen Pharmaceutica Nv	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2763989A1 (fr) *	2011-09-09	2014-08-13	H. Lundbeck A/S	Composés de pyridine et leurs utilisations
WO2013034758A1 (fr) *	2011-09-09	2013-03-14	H. Lundbeck A/S	Triazolopyrazines substituées et leurs utilisations
WO2013034755A1 (fr) *	2011-09-09	2013-03-14	H. Lundbeck A/S	Dérivés de triazolopyrazine et leur utilisation pour le traitement de troubles neurologiques et psychiatriques
CA2872216C (fr)	2012-06-26	2021-07-20	Janssen Pharmaceutica Nv	Combinaisons comprenant des inhibiteurs de la pde 2 tels que des composes 1-aryl-4-methyl-[1,2,4]triazolo [4,3-a]-quinoxaline et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troublesneurologiques ou metaboliques
US20140045856A1 (en)	2012-07-31	2014-02-13	Boehringer Ingelheim International Gmbh	4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
WO2014139983A1 (fr)	2013-03-13	2014-09-18	H. Lundbeck A/S	[1,2,4]triazolo[4,3-a]quinoxalines utilisées en tant que doubles inhibiteurs de pde10/pde2
JP6696904B2 (ja)	2014-01-08	2020-05-20	イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−ＣｅｌｌｕｌａｒＴｈｅｒａｐｉｅｓ，Ｉｎｃ．	製剤および医薬組成物
PL3597649T3 (pl)	2014-04-23	2022-04-04	Dart Neuroscience Llc	Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
WO2016073424A1 (fr)	2014-11-05	2016-05-12	Dart Neuroscience, Llc	Composés 5-méthyl-[1, 2, 4]-triazolo-[1,5-a)-pyrimidin-2-amines substitués utilisés comme inhibiteurs de pde2
KR102557603B1 (ko)	2014-12-06	2023-07-19	인트라-셀룰라 써래피스, 인코퍼레이티드.	유기 화합물
JP6608933B2 (ja)	2014-12-06	2019-11-20	イントラ−セルラー・セラピーズ・インコーポレイテッド	有機化合物
EP3156405A1 (fr)	2015-10-13	2017-04-19	Boehringer Ingelheim International GmbH	Dérivés d'éther spirocycliques de pyrazolo [1,5-a] pyrimidine-3-carboxamide
CA3018784A1 (fr)	2016-03-21	2017-09-28	Perlara Pbc	Composes organiques hererocycliques fusionnes et leurs utilisations
CN106212487B (zh) *	2016-07-28	2018-11-13	浙江工业大学	一种含甲氧基苯并吡嗪结构的1,2,4-三唑衍生物作为杀菌剂的应用
PL3713572T3 (pl)	2017-11-23	2025-09-22	Oslo University Hospital Hf	Leczenie tachykardii
CN116903569B (zh) *	2023-07-06	2025-07-11	常州大学	作为磷酸二酯酶2抑制剂的香豆素-查尔酮杂合类衍生物及其应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5153196A (en)	1991-06-05	1992-10-06	Eli Lilly And Company	Excitatory amino acid receptor antagonists and methods for the use thereof
US6235740B1 (en) *	1997-08-25	2001-05-22	Bristol-Myers Squibb Co.	Imidazoquinoxaline protein tyrosine kinase inhibitors
DE10108752A1 (de)	2001-02-23	2002-09-05	Bayer Ag	Neue Substituierte Imidazotriazinone
WO2004085439A1 (fr) *	2003-03-27	2004-10-07	Pfizer Products Inc.	4-amino[1,2,4]triazolo[4,3-a]quinoxalines substitutees
WO2004096220A1 (fr) *	2003-04-30	2004-11-11	Merck Frosst Canada Ltd.	8-(3-biaryl)phenylquinoleines comme inhibiteurs de la phosphodiesterase de type 4
WO2005041957A1 (fr)	2003-10-29	2005-05-12	Pfizer Products Inc.	Derives d'oxindole et leur utilisation comme inhibiteurs de la phosphodiesterase de type 2
DK1697356T3 (da)	2003-12-16	2009-01-12	Pfizer Prod Inc	Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer
EP1548011A1 (fr)	2003-12-23	2005-06-29	Neuro3D	Dérivés de 1,4-benzodiazépine-2-one comme inhibiteurs de PDE2 phosphodiesterase, leurs préparation et utilisation thérapeutique
FR2870539B1 (fr)	2004-05-19	2006-08-04	Greenpharma Sa Sa	Nouvelles methodes et medicaments
CN101133057B (zh)	2004-09-02	2011-03-09	尼科梅德有限责任公司	三唑并酞嗪化合物
CA2591991C (fr)	2005-01-05	2013-11-19	Altana Pharma Ag	Triazolophthalazines
JP5240899B2 (ja)	2005-01-05	2013-07-17	タケダゲゼルシャフトミットベシュレンクテルハフツング	トリアゾロフタラジン
BRPI0502411A (pt)	2005-03-31	2006-11-28	Univ Minas Gerais	processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
CA2636043A1 (fr)	2006-01-23	2007-08-02	Amira Pharmaceuticals, Inc.	Inhibiteurs tricycliques de la 5-lipoxygenase
WO2007121319A2 (fr)	2006-04-14	2007-10-25	University Of California	Compostions et procédés destinés à déterminer et à prevoir des réponses aux traitements de la dépression et de l'anxiété
TW200817400A (en)	2006-05-30	2008-04-16	Elbion Ag	Pyrido [3,2-e] pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
TW200815436A (en)	2006-05-30	2008-04-01	Elbion Ag	4-amino-pyrido[3,2-e]pyrazines, their use as inhibitors of phosphodiesterase 10, and processes for preparing them
US20080090834A1 (en)	2006-07-06	2008-04-17	Pfizer Inc	Selective azole pde10a inhibitor compounds
DE102006048693A1 (de)	2006-10-14	2008-04-17	Bayer Healthcare Ag	Inhibition der PDE2A
ES2599054T3 (es)	2006-12-13	2017-01-31	Aska Pharmaceutical Co., Ltd.	Derivados de quinoxalina
WO2009070584A1 (fr)	2007-11-30	2009-06-04	Wyeth	Imidazo[1,5-a]pyrazines fusionnées avec aryle et hétéroaryle en tant qu'inhibiteurs de phosphodiestérase 10
WO2009086303A2 (fr)	2007-12-21	2009-07-09	University Of Rochester	Procédé permettant de modifier la durée de vie d'organismes eucaryotes
TWI501965B (zh)	2008-06-20	2015-10-01	Lundbeck & Co As H	作為ｐｄｅ１０ａ酵素抑制劑之新穎苯基咪唑衍生物
AR073574A1 (es)	2008-09-10	2010-11-17	Alcon Res Ltd	Inhibidores heterociclicos de los receptores de histamina para el tratamiento de una enfermedad
US20100120762A1 (en)	2008-11-07	2010-05-13	Wyeth	Triazine derivatives as inhibitors of phosphodiesterases
US8614221B2 (en)	2009-03-11	2013-12-24	Merck Sharp & Dohme Corp.	Inhibitors of Akt activity
WO2010138833A1 (fr) *	2009-05-29	2010-12-02	Wyeth	Imidazo[1,5-a]quinoxalines substituées en tant qu'inhibiteurs de la phosphodiestérase 10
EP2266985A1 (fr)	2009-06-26	2010-12-29	Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts	Dérivés de pyrimidine tricycliques en tant qu'antagonistes Wnt
WO2012096929A2 (fr)	2011-01-11	2012-07-19	Sunovion Pharmaceuticals Inc.	Composés hétéroaryles et leurs procédés d'utilisation
AU2012277912B2 (en)	2011-06-27	2017-03-23	Janssen Pharmaceutica Nv	1-aryl-4-methyl-[1,2,4]triazolo[4,3-a]quinoxaline derivatives
EP2763989A1 (fr)	2011-09-09	2014-08-13	H. Lundbeck A/S	Composés de pyridine et leurs utilisations
WO2013034758A1 (fr)	2011-09-09	2013-03-14	H. Lundbeck A/S	Triazolopyrazines substituées et leurs utilisations
CA2872216C (fr)	2012-06-26	2021-07-20	Janssen Pharmaceutica Nv	Combinaisons comprenant des inhibiteurs de la pde 2 tels que des composes 1-aryl-4-methyl-[1,2,4]triazolo [4,3-a]-quinoxaline et des inhibiteurs de la pde 10 pour utilisation dans le traitement de troublesneurologiques ou metaboliques
US20140045856A1 (en)	2012-07-31	2014-02-13	Boehringer Ingelheim International Gmbh	4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes

2012
- 2012-01-30 US US13/361,002 patent/US9540379B2/en active Active
- 2012-01-31 EP EP12708774.0A patent/EP2670754B1/fr active Active
- 2012-01-31 UY UY0001033888A patent/UY33888A/es not_active Application Discontinuation
- 2012-01-31 SG SG2013057815A patent/SG192210A1/en unknown
- 2012-01-31 GE GEAP201213211A patent/GEP20156333B/en unknown
- 2012-01-31 PE PE2013001585A patent/PE20141023A1/es not_active Application Discontinuation
- 2012-01-31 MX MX2013008667A patent/MX2013008667A/es active IP Right Grant
- 2012-01-31 CN CN2012800157168A patent/CN103459395A/zh active Pending
- 2012-01-31 BR BR112013019354A patent/BR112013019354A2/pt not_active IP Right Cessation
- 2012-01-31 JP JP2013550908A patent/JP6027547B2/ja active Active
- 2012-01-31 WO PCT/EP2012/051546 patent/WO2012104293A1/fr not_active Ceased
- 2012-01-31 AU AU2012213471A patent/AU2012213471B2/en not_active Ceased
- 2012-01-31 MA MA36142A patent/MA34844B1/fr unknown
- 2012-01-31 TW TW101103150A patent/TWI535718B/zh not_active IP Right Cessation
- 2012-01-31 CA CA2824929A patent/CA2824929A1/fr not_active Abandoned
- 2012-01-31 PH PH1/2013/501355A patent/PH12013501355A1/en unknown
- 2012-01-31 EA EA201300871A patent/EA023792B1/ru not_active IP Right Cessation
- 2012-01-31 KR KR1020137023101A patent/KR20140019342A/ko not_active Ceased
- 2012-01-31 AR ARP120100303A patent/AR085099A1/es unknown
- 2012-01-31 UA UAA201310356A patent/UA111963C2/uk unknown
2013
- 2013-06-09 IL IL226826A patent/IL226826A/en not_active IP Right Cessation
- 2013-07-08 CL CL2013002003A patent/CL2013002003A1/es unknown
- 2013-07-29 CO CO13179130A patent/CO6811848A2/es not_active Application Discontinuation
- 2013-07-29 TN TNP2013000325A patent/TN2013000325A1/fr unknown
- 2013-08-13 EC EC2013012824A patent/ECSP13012824A/es unknown

Also Published As

Publication number	Publication date
CL2013002003A1 (es)	2013-12-06
IL226826A (en)	2016-10-31
JP2014503576A (ja)	2014-02-13
BR112013019354A2 (pt)	2019-09-24
EP2670754A1 (fr)	2013-12-11
UA111963C2 (uk)	2016-07-11
NZ611630A (en)	2015-03-27
MX2013008667A (es)	2013-10-01
CO6811848A2 (es)	2013-12-16
TWI535718B (zh)	2016-06-01
TW201245198A (en)	2012-11-16
US20120302564A1 (en)	2012-11-29
EP2670754B1 (fr)	2017-05-24
AU2012213471A1 (en)	2013-07-04
EA023792B1 (ru)	2016-07-29
PE20141023A1 (es)	2014-09-04
CN103459395A (zh)	2013-12-18
UY33888A (es)	2012-08-31
SG192210A1 (en)	2013-09-30
EA201300871A1 (ru)	2014-01-30
KR20140019342A (ko)	2014-02-14
CA2824929A1 (fr)	2012-08-09
GEP20156333B (en)	2015-07-27
MA34844B1 (fr)	2014-01-02
US9540379B2 (en)	2017-01-10
AU2012213471B2 (en)	2016-07-14
ECSP13012824A (es)	2013-10-31
PH12013501355A1 (en)	2013-09-02
JP6027547B2 (ja)	2016-11-16
AR085099A1 (es)	2013-09-11
WO2012104293A1 (fr)	2012-08-09

Publication	Publication Date	Title
TN2013000325A1 (en)	2015-01-20	(1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
PH12013501758A1 (en)	2013-10-14	Pyrazolo [1,5-a] pyridines as trk inhibitors
IN2014DN07384A (fr)	2015-04-24
CA2871471C (fr)	2021-06-01	Inhibiteurs d'adn pk
MX347917B (es)	2017-05-17	Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
PH12012501749A1 (en)	2015-02-25	Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases
MX370814B (es)	2020-01-08	Pirazolo[3,4-d]pirimidinas sustituidas y usos de las mismas.
MX2011012353A (es)	2011-12-14	Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo[2, 3-d]pirimidinas y pirrol-3-il-pirrolo[2,3-d]pirimidinas como inhibidores de la cinasa janus.
TN2014000255A1 (en)	2015-09-30	Disubstituted benzothienyl-pyrrolotriazines and their use as fgfr kinase inhibitors
PH12012500778A1 (en)	2012-11-26	IMIDAZO[1,2-b]PYRIDAZINE DERIVATIVES AND THEIR USE AS PDE10 INHIBITORS
PH12014501829A1 (en)	2014-11-10	Bicyclic pyrazinone derivatives
MX357502B (es)	2018-07-12	Derivados de pirrolotriazinona.
EA201290744A1 (ru)	2013-02-28	Имидазо[1,2-b][1,2,4]триазины в качестве c-met ингибиторов
PH12015501586A1 (en)	2015-10-05	2,3-dihydroimidazol[1,2-c]pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (lp-pla2) inhibitors
MX2014008864A (es)	2014-12-15	Derivados de triazolo[4,5-d]pirimidina.
MX336332B (es)	2016-01-15	Inhibidores de cinasa, formas de profarmaco de los mismos y su uso en terapia.
MX2014011326A (es)	2015-03-20	Derivados de 6-(4-(1-amino-3-hidroxiciclobutil) fenil)-5-fenil (furo, tieno o pirrolo) [2, 3-d] pirimidin 4-ona para el tratamiento de cancer.
MX2015000336A (es)	2015-04-14	Inhibidores de la enzima fosfodiesterasa 10.
MX2014006015A (es)	2014-06-04	Derivados de 3-fenil-isoquinolin-1 (2h) -ona como inhibidores de parp-1.
UA111520C2 (uk)	2016-05-10	[1,2,4]триазолопіридини і їх застосування як інгібіторів фосфодіестерази
TN2013000377A1 (en)	2015-01-20	Thieno [2, 3-d] pyrimidine derivatives and their use to treat arrhythmia
AP3582A (en)	2016-02-08	(1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
HK1189575A (en)	2014-06-13	(1,2,4) triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases